Literature DB >> 25445657

The clinical characteristics and genotype distribution of Chlamydia trachomatis infection in infants less than six months of age hospitalized with pneumonia.

Yuefeng Li1, Likuan Xiong2, Yan Huang1, Yong Xia3, Hua Zhou3, Fen Xu1, Matthew V N O'Sullivan4.   

Abstract

BACKGROUND: Chlamydia trachomatis is a common sexually-transmitted bacterial pathogen. As no routine screening is performed during pregnancy, neonates and infants are at high risk for C. trachomatis infection. The objective of this study was to investigate the morbidity, clinical characteristics and genotype distribution of C. trachomatis pneumonia in infants less than six months of age.
METHODS: Clinical manifestations and laboratory results were recorded. Respiratory sputum specimens were tested using RT-PCR targeting C. trachomatis cryptic plasmid. Simultaneously, respiratory virus antigens were detected by direct immunofluorescence and bacterial pathogens were examined by culture in all sputum samples. Positive C. trachomatis samples were further genotyped using a multiplex PCR reverse line blot assay. The relationship between genotype and pneumonia severity was explored.
RESULTS: Of 1408 infants, 101 (7.2%) were infected with C. trachomatis. Sixteen of 101 (15.8%) were assessed as severe pneumonia. These severe cases had a higher proportion of viral co-infection (37.5%) compared to mild pneumonia cases (9.4%, P<0.05).Infants with tachypnea (OR 9.2) and wheezing (OR 3.5) were more likely to be classified as severe pneumonia (P<0.05). Amongst 66 C. trachomatis specimens for which a genotyping result was available, seven genotypes were detected, and 39.4% of these specimens contained two or three genotypes. Overall, genotype E (48.5%) was the most frequent, followed by genotype F (42.4%), J (31.8%), D (12.1%), K (10.6%), G (4.5%) and H (3.0%). There were no significant correlations of particular genotypes with severity of disease, although there was a weak indication that more severe pneumonia might be associated with having certain mixed genotypes of C. trachomatis.
CONCLUSIONS: The prevalence of C. trachomatis in the population of young hospitalized infants with pneumonia in Shenzhen was very high. The relationship between genotype distribution and severity of pneumonia was not clear based on this study due to small sample size. Further in-depth investigation correlating genotype and disease severity based on a larger population is needed.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  Chlamydia trachomatis; Genotyping; Reverse line blot hybridization

Mesh:

Substances:

Year:  2014        PMID: 25445657     DOI: 10.1016/j.meegid.2014.11.004

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  4 in total

1.  Clinical evaluation of a new single-tube multiplex reverse transcription PCR assay for simultaneous detection of 11 respiratory viruses, Mycoplasma pneumoniae and Chlamydia in hospitalized children with acute respiratory infections.

Authors:  Meng-Chuan Zhao; Gui-Xia Li; Dan Zhang; Hang-Yu Zhou; Hao Wang; Shuo Yang; Le Wang; Zhi-Shan Feng; Xue-Jun Ma
Journal:  Diagn Microbiol Infect Dis       Date:  2017-03-22       Impact factor: 2.803

2.  Comparison of reverse hybridization and ompA sequencing methods applied on Chlamydia trachomatis strains from Tunisia.

Authors:  Houda Gharsallah; Olfa Frikha-Gargouri; Reinier J Bom; Adnene Hammami; Sylvia M Bruisten
Journal:  Microbiologyopen       Date:  2017-12-28       Impact factor: 3.139

3.  Tetracycline Selective Pressure and Homologous Recombination Shape the Evolution of Chlamydia suis: A Recently Identified Zoonotic Pathogen.

Authors:  Sandeep J Joseph; Hanna Marti; Xavier Didelot; Timothy D Read; Deborah Dean
Journal:  Genome Biol Evol       Date:  2016-09-02       Impact factor: 3.416

4.  Current Research of Chlamydial Infection Diseases in China.

Authors:  Xue Li; Qing-Feng Liang; Guan-Yu Su; Li-Yuan Wu; Xin-Xin Lu; Ning-Li Wang
Journal:  Chin Med J (Engl)       Date:  2018-02-20       Impact factor: 2.628

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.